Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

A 1996 update on antihypertensive agents

J M Sullivan1

  • 1University of Tennessee, Memphis 38163, USA.

Current Opinion in Cardiology
|September 1, 1996
PubMed
Summary
This summary is machine-generated.

New antihypertensive agents, including neutral endopeptidase inhibitors and angiotensin II receptor blockers, are under development. Research also covers endothelin inhibitors, carvedilol, thiazide diuretics, and a review of calcium-channel blockers for hypertension management.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Kinetic and thermodynamic acidity of hydrido transition-metal complexes. 3. Thermodynamic acidity of common mononuclear carbonyl hydrides.

Journal of the American Chemical Society·2011
Same author

The influence of cause-specific mortality conditions on the age pattern of mortality with special reference to Taiwan.

Population studies·2011
Same author

Models for the estimation of the probability of dying between birth and exact ages of early childhood.

Population studies·2011
Same author

Shock in forward areas.

Wisconsin medical journal·2010
Same author

Foreign body in the stomach.

Wisconsin medical journal·2010
Same author

Traumatic shock.

Marquette medical review·2010

Area of Science:

  • Pharmacology and Therapeutics
  • Cardiovascular Medicine
  • Drug Development

Background:

  • Hypertension remains a leading cause of cardiovascular morbidity and mortality worldwide.
  • There is a continuous need for novel antihypertensive agents with improved efficacy and safety profiles.
  • Existing treatments present challenges, necessitating exploration of new therapeutic classes and strategies.

Purpose of the Study:

  • To outline emerging classes of antihypertensive agents currently in development.
  • To review clinical and experimental data on novel drug candidates and existing drug classes.
  • To provide insights into current controversies and recommendations in hypertension management.

Main Methods:

  • Review of clinical trial data for neutral endopeptidase inhibitors and angiotensin II receptor blockers.

Related Experiment Videos

  • Summary of experimental studies on endothelin inhibitors.
  • Presentation of clinical and experimental findings for carvedilol, a multi-action agent.
  • Analysis of studies on very low-dose thiazide diuretics.
  • Reporting of a meta-analysis on non-potassium-sparing diuretics and sudden death risk.
  • Review of the literature and current recommendations regarding calcium-channel blockers.

    • Main Results:

    • Several new classes of antihypertensive agents are in development, showing promise for future treatment options.
    • Clinical and experimental data support the investigation of neutral endopeptidase inhibitors, angiotensin II receptor blockers, and endothelin inhibitors.
    • Carvedilol demonstrates efficacy as a multi-action antihypertensive agent.
    • Very low doses of thiazide diuretics can enhance the efficacy of other antihypertensive medications.
    • A meta-analysis indicated an increased risk of sudden death with non-potassium-sparing diuretics in hypertensive patients.
    • Controversies surrounding calcium-channel blockers persist, with specific recommendations for rapidly-acting nifedipine.

    Conclusions:

    • The landscape of antihypertensive therapy is evolving with the development of novel agents and refined use of existing ones.
    • Careful consideration of drug class risks and benefits, such as with non-potassium-sparing diuretics and calcium-channel blockers, is crucial.
    • Further research and clinical evaluation are necessary to optimize the use of these agents in managing hypertension.